ArticleInternational journal of proteomics2011
Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.
Article in International journal of proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Circulating enolase 1 as a diagnostic biomarker for early-stage breast cancer.NPJ precision oncology · 2025Article
- Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.Journal of personalized medicine · 2025Review
- Advancements in Single-Cell Proteomics and Mass Spectrometry-Based Techniques for Unmasking Cellular Diversity in Triple Negative Breast Cancer.Proteomics. Clinical applications · 2025Review
- Function and mechanism of action of the TRPV1 channel in the development of triple-negative breast cancer.Acta biochimica et biophysica Sinica · 2024Review
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.Journal of cellular and molecular medicine · 2022Review
- Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.Cancers · 2021Article
- Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis.Cancers · 2021Review
- Proteomic Differences in Feline Fibrosarcomas Grown Using Doxorubicin-Sensitive and -Resistant Cell Lines in the Chick Embryo Model.International journal of molecular sciences · 2018Article
- Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis.Oncology letters · 2017Article
- Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.Molecular bioSystems · 2016Review
- Proteomic analysis reveals that the protective effects of ginsenoside Rb1 are associated with the actin cytoskeleton in β-amyloid-treated neuronal cells.Journal of ginseng research · 2016Article
- Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.Cancer biology & therapy · 2016Article
- Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics.EuPA open proteomics · 2016Article
- Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.BMC medicine · 2015Article
- Quantitative iTRAQ LC-MS/MS proteomics reveals the proteome profiles of DF-1 cells after infection with subgroup J Avian leukosis virus.BioMed research international · 2015Article
- microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.Oncotarget · 2014Article
- Mammalian adenylyl cyclase-associated protein 1 (CAP1) regulates cofilin function, the actin cytoskeleton, and cell adhesion.The Journal of biological chemistry · 2013Article
- Alpha-actinin 4 and tumorigenesis of breast cancer.Vitamins and hormones · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Protein-based markers that classify tumor subtypes and predict therapeutic response would be clinically useful in guiding patient treatment. We investigated the LC-MS/MS-identified protein biosignatures in 39 baseline breast cancer specimens including 28 HER2-positive and 11 triple-negative (TNBC) tumors. Twenty proteins were found to correctly classify all HER2 positive and 7 of the 11 TNBC tumors. Among them, galectin-3-binding protein and ALDH1A1 were found preferentially elevated in TNBC, whereas CK19, transferrin, transketolase, and thymosin β4 and β10 were elevated in HER2-positive cancers. In addition, several proteins such as enolase, vimentin, peroxiredoxin 5, Hsp 70, periostin precursor, RhoA, cathepsin D preproprotein, and annexin 1 were found to be associated with the tumor responses to treatment within each subtype. The MS-based proteomic findings appear promising in guiding tumor classification and predicting response. When sufficiently validated, some of these candidate protein markers could have great potential in improving breast cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.